Semaglutide plus cagrilintide — an amylin analog — in one weekly pen: the combination that posted ≈−22.7% in REDEFINE-1’s 2024 topline, aiming past tirzepatide. Not approved; nothing sold under this name today is a legitimate pharmaceutical.
Deeper data: the trial index holds every figure above with sources; where the pipeline points, the standing warning.
CagriSema is Novo Nordisk’s answer to tirzepatide: semaglutide 2.4 mg co-formulated with cagrilintide, a long-acting amylin analog — a second satiety hormone rather than a second incretin.
The amylin idea
Amylin is co-secreted with insulin and acts on satiety circuits distinct from GLP-1’s. Stacking the two mechanisms aims at additive appetite suppression — a different bet than tirzepatide’s GIP pairing, which makes the eventual head-to-head genuinely interesting science.
What the trials have reported
Company-reported topline from REDEFINE-1 (obesity, late 2024) put average weight loss around 22.7% — a strong number that nonetheless missed the ~25% expectation the market had priced in; REDEFINE-2 (type 2 diabetes, 2025) reported roughly 15.7%. Peer-reviewed publications and regulatory filings should be checked for current status — timelines pointed to submission around 2026 as of our last verification.
Why it matters for buyers who can’t buy it
Pipeline pressure is pricing pressure. A credible second ≥20% agent changes negotiating dynamics for employers, insurers, and cash channels well before launch — context for every number in our ledger. And as with every pipeline name: nothing sold today under “cagrilintide” outside a trial is legitimate (warning file).
How it would slot into the market
CagriSema is Novo’s bid to reclaim the efficacy crown tirzepatide took — built on the same 2.4 mg semaglutide backbone its Wegovy infrastructure already manufactures at scale, which matters for launch supply in a way a novel molecule wouldn’t. The strategic subplot: reported topline in the low-20s landed close enough to tirzepatide’s numbers that the eventual marketing fight will be waged in subgroups, tolerability, and price — an outcome that serves buyers better than a runaway winner would.
The side-effect signal so far
Company disclosures point to a gastrointestinal profile broadly familiar from the class, with amylin’s nausea contribution the open question at scale — amylin analogs have their own GI history. As with every pipeline file on this site: topline safety summaries are marketing until the peer-reviewed data lands, and we’ll update this file when it does.
Related programs
Cagrilintide is also being studied alone and in other pairings — amylin agonism is a platform, not a one-off — so expect the name to surface beyond CagriSema. The gray-market rule extends to all of it: no compounded or “research” cagrilintide product has any legitimate route to a consumer today.
References
REDEFINE-1 and REDEFINE-2 topline disclosures, Novo Nordisk 2024–2025 — verify against subsequent peer-reviewed publications.